First stem cell drug approved for systemic disease treatment

Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. Osiris shares rose 14 percent to $6.00 in extended trading after the news was announced. Continue reading

Family hangs hope for boy on unproven therapy in India

Indian clinic’s stem cell therapy real? STORY HIGHLIGHTS For more of CNN correspondent Drew Griffin’s investigation of India’s experimental embryonic stem cell therapy, watch “CNN Presents: Selling a Miracle,” at 8 and 11 p.m. ET Sunday on CNN. Continue reading

Medical success or boondoggle?

Indian clinic’s stem cell therapy real? STORY HIGHLIGHTS For more of CNN correspondent Drew Griffin’s investigation of India’s experimental embryonic stem cell therapy, watch “CNN Presents: Selling a Miracle,” at 8 and 11 p.m. Continue reading

Scientists Discover Marker to Identify, Attack Breast Cancer Stem Cells

Cell surface protein blows potent cells cover; targeted drug works in preclinical tests Newswise HOUSTON Breast cancer stem cells wear a cell surface protein that is part nametag and part bulls eye, identifying them as potent tumor-generating cells and flagging their vulnerability to a drug, researchers at The University of Texas MD Anderson Cancer Center report online in Journal of Clinical Investigation. Continue reading

QualityStocks News – International Stem Cell Scientists to Present Pre-Clinical Research Results at Gene and Cell …

Results to demonstrate broad application of parthenogenetic stem cells.Scottsdale, AZ (PRWEB) May 16, 2012 QualityStocks would like to highlight International Stem Cell Corporation, a publicly traded company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core … Continue reading

Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant

Public release date: 15-May-2012 [ | E-mail | Share ] Contact: Elisa Williams willieli@ohsu.edu 503-494-4530 Oregon Health & Science University PORTLAND, Ore. Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute. The study, published in the New England Journal of Medicine, found a 63 percent reduction in the risk of progressive myeloma or death for the stem cell transplant patients that were treated with lenalidomide maintenance therapy Continue reading

Stem cell therapy to treat a chimp's torn ACL may prove beneficial for humans

Veterinarians hope a new medical procedure can treat a 25-year-old chimpanzee with a torn ACL, or anterior cruciate ligament, at the “Save the Chimps” in Florida. The procedure involves injecting the chimp with her own stem cells Continue reading

Vet undertakes stem cell surgery

Animal stem cell regenerative therapy is the newest service at the Animal Hospital of Tiffin. “We are the official first site for the therapy in Ohio,” said veterinarian Bob McClung. The technology uses an adult animal’s stem cells to heal itself Continue reading

International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene …

CARLSBAD, Calif.–(BUSINESS WIRE)– International Stem Cell Corporation (OTCBB: ISCO.OB – News) (www.internationalstemcell.com) today announced that several of its leading scientists will present experimental results from three of ISCOs pre-clinical therapeutic programs. Firstly, the application of A9 dopaminergic neurons derived from human parthenogenetic stem cells (hpSC) for the treatment of Parkinsons disease Continue reading

Joseph Estrada defies age, shares how he did it: Stem cell therapy

By Cathy C. Yamsuan Philippine Daily Inquirer Former President Joseph Erap Estrada had always maintained that giving generously to friends and forgiving opponents are the secrets to staying young. But time has a way of catching up with even the most formidable leading men Continue reading

Using Stem Cell Therapy For Neck And Head Cancers Avoids Salivary Gland Damage Caused By Radiotherapy

Editor’s Choice Main Category: Ear, Nose and Throat Also Included In: Radiology / Nuclear Medicine;Cancer / Oncology;Stem Cell Research Article Date: 11 May 2012 – 10:00 PDT Current Article Ratings: The researchers note this finding could enhance the quality of life of 500,000 individuals with head and neck cancer each year worldwide. The team found that the stem cells needed for regenerating the parotid gland (the largest pair of salivary glands) were primarily located in the major ducts of the gland Continue reading

Stem Cell Study Shows Promising Results Against Heart Failure

By Denise Mann HealthDay Reporter THURSDAY, May 10 (HealthDay News) — A new treatment that involves spinning bone marrow stem cells to enhance their healing potential may help people with advanced heart failure feel and function better, a small study suggests. Researchers developed the treatment by culturing a patient’s own bone marrow for 12 days. This process helped increase the amount of immune cells and stem cells that can differentiate into several different cell types, including heart cells. Continue reading

New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly …

BOUDRY, Switzerland–(BUSINESS WIRE)– Celgene International Srl, a subsidiary of Celgene Corporation (NASDAQ: CELG – News), today announced that results from three phase III studies evaluating the use of continuous REVLIMID (lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine. All three publications highlight the expanding body of clinical evidence supporting lenalidomide treatment in these areas. Continuous Lenalidomide Therapy (non-transplant eligible population): The first article highlights a Celgene-sponsored study of continuous lenalidomide treatment in elderly patients newly diagnosed with multiple myeloma Continue reading